Tuberculosis in Indonesia : Epidemic Projections and Opportunities to Accelerate Control
Indonesia is the third largest contributor to the global tuberculosis (TB) burden and among the top twenty countries in the world for TB-HIV (human immunodeficiency virus) coinfection, and multidrug-resistant TB (MDR-TB). In addition to the signifi...
| Main Authors: | , , |
|---|---|
| Format: | Report |
| Language: | English |
| Published: |
World Bank, Washington, DC
2021
|
| Subjects: | |
| Online Access: | http://documents.worldbank.org/curated/en/907681617019898576/Tuberculosis-in-Indonesia-Epidemic-Projections-and-Opportunities-to-Accelerate-Control http://hdl.handle.net/10986/35370 |
| Summary: | Indonesia is the third largest
contributor to the global tuberculosis (TB) burden and among
the top twenty countries in the world for TB-HIV (human
immunodeficiency virus) coinfection, and multidrug-resistant
TB (MDR-TB). In addition to the significant toll of TB to
health and human capital, the economic burden of TB is
substantial. Controlling TB in Indonesia will require not
only that the Government of Indonesia (GOI) spend more on TB
but that it spend it better. This means that decisions on
which interventions or programs to prioritize and how best
to implement them will be critical to maximizing health
outcomes. Projections indicate that TB incidence will remain
relatively stagnant under status quo spending and that there
is limited scope for improving allocative efficiency.
Following a request for technical assistance from the
Government of Indonesia (GOI) on how to make available TB
resources go further, especially in a context of shrinking
external funding, consultations were held with program
managers and experts in the National TB Program, the
Ministry of Health, and the Ministry of Finance. Optima TB
is a mathematical optimization model that informs policy
makers and program managers on how to allocate the available
resources across TB programs to maximize impact. This report
covers the findings from an Optima TB analysis conducted in
Indonesia as of September 2020. |
|---|